Cerevel Therapeutics appointed Paul Burgess as Chief Business Development and Strategic Operations Officer, effective June 20. Burgess’s most recent role was COO and CLO of Translate Bio. At Translate Bio, he led business development, legal, program management, quality, technical operations and partner collaborations. He joined Translate Bio in 2015 and remained until 2021. Prior to Translate Bio, Burgess worked in a legal role at a number of companies including Scholar Rock, Civitas Therapeutics, BIND Therapeutics and Transform Pharmaceuticals
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CERE:
- Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer
- Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer
- Cerevel Therapeutics reports Q1 EPS (67c), consensus (67c)
- Cerevel Therapeutics appoints Ron Renaud as CEO
- Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results